111, Inc. (YI) is a leading integrated online and offline healthcare platform that revolutionizes the healthcare industry through its digital transformation and optimization process. The company, which is listed on the NASDAQ and headquartered in Shanghai, China, aims to deliver better healthcare solutions by actively pursuing plans to build an ecosystem combining both online and offline elements.
111, Inc. utilizes a wide range of digital and technological resources to aggregate healthcare resources, implement data analytics, human capital management systems, and operate cloud-based solutions to better equip pharmacies. The company combines the power of technology with the extensive industry knowledge of its dedicated team to provide customers with superior healthcare experience.
One of the main services of 111, Inc. is forming strategic partnerships with pharmaceutical manufacturers, retail pharmacies, and private hospitals. The company boasts of an artificial intelligence-backed platform for pharmaceutical companies where they can efficiently manage their supply chain process. Through its robust online platform, registered pharmacies can access real-time inventory, sales data, and analytical support which significantly aids in managing businesses.
111, Inc. also offers B2C services through its Online-to-Offline (O2O) pharmaceutical e-commerce platform known as "1 Drugstore". This online platform was designed to increase access to pharmaceutical products for consumers and also to educate them about various health topics.
For patients, 111, Inc. has a telemedicine service called "1 Clinic", which allows patients to have online consultations with renowned doctors from China's top-tier hospitals. The company also operationalizes the "1 Drug Mall", a B2B2C pharmaceutical e-commerce platform that connects manufacturers with consumers.
Thematically, all the services offered by 111, Inc. are bound by its vision to improve China’s healthcare system via digital transformation. The company applies advanced technologies to the healthcare landscape with the end goal of improving billions of lives.
111, Inc.'s innovative strategies and commitment towards providing top-notch healthcare services have cemented its position as a prominent player in China's healthcare industry. As the company moves forward, it continues to pioneer innovative healthcare solutions, contributing to reshaping the future of healthcare in terms of access, quality, and affordability.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Co-founders Dr. Gang Yu and Junling Liu, along with Huadeng Tech BioArray Ventures Ltd, have proposed an all-cash deal to take 111, Inc. private. The proposal offers US$4.52 per ADS, representing a significant premium over recent trading prices. The deal is non-binding and subject to review by a special committee of independent directors, with no assurance that a definitive agreement will be reached.
111, Inc. has received an unsolicited, preliminary, and non-binding acquisition proposal, which could lead to a change in ownership. The offer letter was signed by CEO Junling Liu on September 17, 2026, and is still in its early, non-finalized stages. This development suggests a potential transaction rather than a confirmed change in company ownership.